End-of-day quote
Egyptian Exchange
06:00:00 2024-06-01 pm EDT
|
5-day change
|
1st Jan Change
|
2.27
EGP
|
-3.40%
|
|
0.00%
|
+37.58%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,543
|
2,928
|
2,400
|
2,892
|
2,459
|
3,384
|
-
|
-
|
Enterprise Value (EV)
1 |
3,637
|
3,339
|
2,761
|
2,892
|
3,223
|
4,450
|
4,150
|
3,597
|
P/E ratio
|
43
x
|
30
x
|
14.4
x
|
12.9
x
|
11.1
x
|
7.64
x
|
5.83
x
|
4.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
4.67%
|
7.75%
|
-
|
Capitalization / Revenue
|
3.96
x
|
3.05
x
|
1.93
x
|
1.95
x
|
1.28
x
|
1.16
x
|
0.96
x
|
0.86
x
|
EV / Revenue
|
4.07
x
|
3.48
x
|
2.21
x
|
1.95
x
|
1.68
x
|
1.53
x
|
1.17
x
|
0.91
x
|
EV / EBITDA
|
14.3
x
|
13.7
x
|
8.63
x
|
6.83
x
|
6.28
x
|
5.23
x
|
3.93
x
|
3.03
x
|
EV / FCF
|
51.7
x
|
-9.14
x
|
-
|
-
|
-10.8
x
|
12.6
x
|
15
x
|
9.34
x
|
FCF Yield
|
1.93%
|
-10.9%
|
-
|
-
|
-9.25%
|
7.91%
|
6.69%
|
10.7%
|
Price to Book
|
3.3
x
|
2.47
x
|
1.78
x
|
-
|
1.4
x
|
1.54
x
|
1.43
x
|
0.96
x
|
Nbr of stocks (in thousands)
|
1,522,533
|
1,522,533
|
1,522,534
|
1,482,613
|
1,490,530
|
1,490,530
|
-
|
-
|
Reference price
2 |
2.327
|
1.923
|
1.576
|
1.951
|
1.650
|
2.270
|
2.270
|
2.270
|
Announcement Date
|
2/18/20
|
3/2/21
|
2/24/22
|
3/7/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
894
|
960.2
|
1,246
|
1,484
|
1,922
|
2,918
|
3,533
|
3,932
|
EBITDA
1 |
253.5
|
243.9
|
319.8
|
423.2
|
513
|
851
|
1,056
|
1,188
|
EBIT
1 |
217.3
|
187.6
|
273.6
|
357.7
|
440.1
|
772.2
|
977.5
|
1,219
|
Operating Margin
|
24.31%
|
19.54%
|
21.95%
|
24.11%
|
22.89%
|
26.47%
|
27.67%
|
31%
|
Earnings before Tax (EBT)
1 |
-
|
145.1
|
233.6
|
328.5
|
327.4
|
595.7
|
760.7
|
956.2
|
Net income
1 |
-
|
112.2
|
181.1
|
245.7
|
244.9
|
388.4
|
534
|
716
|
Net margin
|
-
|
11.68%
|
14.53%
|
16.56%
|
12.74%
|
13.31%
|
15.11%
|
18.21%
|
EPS
2 |
0.0541
|
0.0640
|
0.1093
|
0.1518
|
0.1489
|
0.2971
|
0.3891
|
0.4789
|
Free Cash Flow
1 |
70.35
|
-365.4
|
-
|
-
|
-298
|
352
|
277.5
|
385
|
FCF margin
|
7.87%
|
-38.06%
|
-
|
-
|
-15.5%
|
12.06%
|
7.85%
|
9.79%
|
FCF Conversion (EBITDA)
|
27.75%
|
-
|
-
|
-
|
-
|
41.36%
|
26.27%
|
32.41%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
90.62%
|
51.97%
|
53.77%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.1060
|
0.1760
|
-
|
Announcement Date
|
2/18/20
|
3/2/21
|
2/24/22
|
3/7/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
---|
Net sales
1 |
450.4
|
842.4
|
542.7
|
534.2
|
1,080
|
EBITDA
1 |
-
|
-
|
-
|
138.3
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
49.16
|
115.7
|
71.6
|
52.9
|
129.2
|
Net margin
|
10.91%
|
13.73%
|
13.19%
|
9.9%
|
11.96%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/15/23
|
8/15/23
|
11/14/23
|
3/19/24
|
3/19/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
93.4
|
410
|
361
|
-
|
763
|
1,067
|
766
|
214
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.3682
x
|
1.683
x
|
1.127
x
|
-
|
1.488
x
|
1.254
x
|
0.7251
x
|
0.1798
x
|
Free Cash Flow
1 |
70.3
|
-365
|
-
|
-
|
-298
|
352
|
278
|
385
|
ROE (net income / shareholders' equity)
|
10.8%
|
9.94%
|
14.3%
|
17.3%
|
14.9%
|
22.4%
|
23.6%
|
22.6%
|
ROA (Net income/ Total Assets)
|
5.39%
|
5.45%
|
7.76%
|
9.57%
|
8.17%
|
11%
|
11%
|
-
|
Assets
1 |
-
|
2,058
|
2,335
|
2,567
|
2,996
|
3,531
|
4,855
|
-
|
Book Value Per Share
2 |
0.7000
|
0.7800
|
0.8900
|
-
|
1.180
|
1.470
|
1.590
|
2.360
|
Cash Flow per Share
2 |
0.0400
|
-0.1100
|
0.1600
|
0.0200
|
-0.0300
|
-0.1300
|
0.1200
|
0.6500
|
Capex
1 |
90.8
|
201
|
238
|
128
|
253
|
120
|
221
|
257
|
Capex / Sales
|
10.16%
|
20.95%
|
19.11%
|
8.64%
|
13.19%
|
4.11%
|
6.25%
|
6.53%
|
Announcement Date
|
2/18/20
|
3/2/21
|
2/24/22
|
3/7/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
2.27
EGP Average target price
4.378
EGP Spread / Average Target +92.86% Consensus |
1st Jan change
|
Capi.
|
---|
| +37.58% | 71.58M | | +40.73% | 739B | | +31.57% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.34% | 240B | | +9.44% | 210B | | -5.52% | 206B | | +6.17% | 164B |
Other Pharmaceuticals
|